Navigation Links


TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports

9/2/2014
PHILADELPHIA , Sept. 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") today announced that it has developed a recommended approach for protecting personal data in Clinical Study Reports (CSRs) that are shared with researchers, patients and others. The document describes an approach to apply when redacting or removing personal information from CSRs and othe... [Comments]

Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas

9/2/2014
AVENTURA, Fla. , Sept. 2, 2014  Technology Applications International Corporation (the "Company" or "NUUU")(OTC BB: NUUU) has announced that its wholly-owned subsidiary Renuell Int'l, Inc. has signed an additional exclusive licensing agreement with the National Aeronautics and Space Administration ("NASA") at the Johnson Space Center in Houston , Texas.  See pho... [Comments]

Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid

9/2/2014
Quincy, MA (PRWEB) September 02, 2014 Myriant Corporation, a global renewable chemicals company, announced today the signage of a distribution agreement with Azelis Group, a specialty chemicals distribution leader. Azelis is now distributing Myriant’s bio-succinic acid in the Nordics, Benelux, France, Iberia, Italy, the United Kingdom and Ireland, targeting customers in the industrial and b... [Comments]

Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology

9/2/2014
Philadelphia, PA (PRWEB) September 02, 2014 Opertech Bio, Inc., a company that has pioneered a new highly efficient, cost effective approach to sensory evaluation, today announced the issuance of U.S. Patent No. 8,820,265 by the U.S. Patent and Trademark Office, encompassing high-throughput sensory discrimination technologies proprietary to Opertech. “Opertech’s taste evaluation techno... [Comments]

Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent

9/2/2014
SAN DIEGO , Sept. 2, 2014 Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today announced that the U.S. Patent and Trademark Office (PTO) has issued a patent related to NB32, the Company's investigational medication being evaluated for weight loss. NB32 is a fixed-dose combination of naltrexone sustained release (SR) and bupropion SR. U.S. Patent No. 8,815,889 claims methods f... [Comments]

Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel

9/2/2014
MONROVIA, Calif. , Sept. 2, 2014  Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Debra Zack , M.D., Ph.D., vice president, clinical development and the appointment of Lloyd Rowland ,... [Comments]

Oncothyreon to Present at Rodman & Renshaw Global Investment Conference

9/2/2014
SEATTLE , Sept. 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced today that Robert Kirkman , M.D., President and Chief Executive Officer, will present at the Rodman & Renshaw 16 th Annual Global Investment Conference in New York on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. A live and archived webcast of the presentation will be accessible by visiting th... [Comments]

Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections

9/2/2014
ROCKVILLE, Md. , Sept. 2, 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical toxicology study of SYN-004. Per U.S. Food and Drug Administration (FDA) guidance, this bridging study... [Comments]

BIOREM announces $2.1 million of new orders

9/2/2014
GUELPH, ON , Sept. 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced three new orders totalling $2.1 million. The orders consist of three large odour control systems for waste water treatment plants in Canada . "These orders are consistent with the market resurgence in North America ," said Peter Bruijns , President and CEO. "After a diff... [Comments]

PMG Research Announces the Formation of its Eleventh Site

9/2/2014
Winston-Salem, NC and Rocky Mount, NC (PRWEB) September 02, 2014 PMG Research, Inc . (PMG) announced today the establishment of its 11th clinical research site: PMG Research of Rocky Mount. Effective September 1, PMG Research has assumed ownership and operation of the clinical research department at Boice-Willis Clinic in Rocky Mount, NC, further expanding PMG’s presence in eastern North... [Comments]

[previous] [next]
(Date:9/2/2014)... accidentally touch a hot oven, you rapidly pull your ... involved in sensing and responding to such painful stimuli, ... Duke researchers have made a surprising discovery about the ... worms, and have built a structural model of the ... Communications , may help direct new strategies to treat ...
(Date:9/1/2014)... ─ Dietary quality in the U.S. has improved steadily ... fat intakebut overall dietary quality remains poor and disparities ... to a new study from Harvard School of Public ... evidence to date that the extensive efforts by many ... having some payoff, but it also indicates that these ...
(Date:9/1/2014)... Within minutes after birth, every child in the U.S. ... host of conditions, including sickle cell disease. Thousands of ... lucky, meaning many suffer and die from the disease ... a halt to at least some of those deaths. ... Biology working in the lab of George Whitesides, the ...
Breaking Biology News(10 mins):Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3
... connection between the body, mind and spirit has been ... years. The notion that psychosocial and societal considerations have ... crystallized as a result of the experiences of a ... writer and magazine editor of the popular Saturday Review, ...
... / b3c newswire / - Addressing significant product safety and ... has announced the commercial launch of two protease-free ... Albumin-DX (Lipid-Free) perform better in diagnostics applications than ... serum albumin (pHSA).  , , ...
... is a tragic disease that robs an individual of their memory ... 65 now suffer from the disease and one in two people ... Alzheimer,s does not only affect the elderly. Familial Alzheimer,s disease (FAD), ... The Study , Alzheimer,s is a complex ...
Cached Biology News:Laughter remains good medicine 2Laughter remains good medicine 3InVitria Announces Launch of Recombinant Albumin for Diagnostics 2Computational model examines the pathways of Alzheimer's that strikes at the young 2
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
... BD PhosFlow Perm/Wash Buffer I can be ... signaling proteins to permeabilize cells and to ... wash buffer. Because saponin-mediated cell permeabilization is ... keep the cells in the presence of ...
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Biology Products:
(Date:8/29/2014)... 29, 2014  Pfenex Inc. (NYSE MKT: PFNX), ... of high-value and difficult to manufacture proteins including ... reported financial results for the second quarter ended ... completion of our initial public offering, we have ... product candidates, derived from our proprietary protein expression ...
(Date:8/29/2014)... 29, 2014 The global companion ... in 2019. It is expected to grow at ... and was valued at $1.8 billion in 2013, ... Market Research. , For more information regarding analysis ... , The research report, titled “Companion Diagnostics Market ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... Chairman, Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, ... JASIS on September 5, 2014. JASIS , Asia’s ... September 3-5, 2014, in Makuhari Messe, Japan. , ... New Tools for Bioanalysis from Single Molecules to Single ...
(Date:8/29/2014)... 2014 Local veterinarian, Dr. Keith Clement, ... seeking candidates to participate in an investigational study of ... ultimate goal of this study is to determine if ... or two arthritically affected joints can help reduce pain ... for the current investigational study must be older than ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... today its financial results for the year ending 31,December 2008. , , ... regulatory process for intravenous iclaprim in US, - ... of "intravenous-to-oral" Phase II trial with oral, ... - Share placing, Cash and financial investments of ...
... better restaurant menu optionsINDIANAPOLIS, Feb. 25 This year,s ... America with the reduction of nearly a half billion ... three years. Since the market introduction in 2006, Omega-9 ... replaced more than 340 million pounds of trans fat, ...
... collaborative agreement with CureDM to continue the preclinical development of CureDM,s HIP2B ... , ... Cary, NC (PRWEB) February 25, 2009 -- Calvert ... the signing of a collaborative agreement with CureDM to continue ...
Cached Biology Technology:Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5Heart Health Month Milestone: Half a Billion Pounds of Bad Fats Eliminated From North American Diet 2Heart Health Month Milestone: Half a Billion Pounds of Bad Fats Eliminated From North American Diet 3Calvert Research and CureDM Sign Collaborative Agreement 2Calvert Research and CureDM Sign Collaborative Agreement 3